EICHORCondition: Graves' Disease · Sponsor: Immunovant Sciences GmbH
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
This description comes directly from the study's public registry record.
Central Study Contact · 18007970414 · clinicaltrials@immunovant.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures. * Male or female participants aged ≥ 18 years. * Participants with diagnosis of GD who are hyperthyroid despite ATD treatment. * Other, more specific inclusion criteria are defined in the protocol. Exclusion Criteria: * Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy. * Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk. * Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation. * Additional exclusion criteria are defined in the protocol.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Site Number - 1032 | Phoenix, Arizona, United States | Withdrawn |
| Site Number - 1036 | Phoenix, Arizona, United States | Recruiting |
| Site Number - 1061 | Huntington Beach, California, United States | Recruiting |
| Site Number - 1001 | Los Angeles, California, United States | Recruiting |
| Site Number - 1047 | Los Angeles, California, United States | Recruiting |
| Site Number - 1062 | Orange, California, United States | Recruiting |
| Site Number - 1046 | Sacramento, California, United States | Recruiting |
| Site Number - 1034 | San Francisco, California, United States | Recruiting |
| Site Number - 1035 | Santa Clarita, California, United States | Withdrawn |
| Site Number - 1005 | Torrance, California, United States | Recruiting |
| Site Number - 1006 | Walnut Creek, California, United States | Withdrawn |
| Site Number - 1013 | Englewood, Colorado, United States | Recruiting |
+ 122 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06727604